Dr. Pawel A. Mroz Profile

Dr. Pawel A. Mroz

Visiting Scientist at Wellman Ctr for Photomedicine

SPIE Involvement:

Author

Publications (11)

Proceedings Article | 9 February 2012 Paper

Photodynamic therapy can induce non-specific protective immunity against a bacterial infection

Masamitsu Tanaka, Pawel Mroz, Tianhong Dai, Manabu Kinoshita, Yuji Morimoto, Michael Hamblin

Proceedings Volume 8224, 822403 (2012) https://doi.org/10.1117/12.906012

KEYWORDS: Photodynamic therapy, Bacteria, Tissues, Defense and security, Image processing, Light emitting diodes, In vivo imaging, Statistical analysis, Data analysis, Surgery

Read Abstract +

Proceedings Article | 9 February 2011 Paper

The potential role of functional inhibition of T regulatory cells by anti-TGF-beta antibody in photodynamic therapy of renal cancer

Pawel Mroz, Michael Hamblin

Proceedings Volume 7900, 790003 (2011) https://doi.org/10.1117/12.876523

KEYWORDS: Tumors, Photodynamic therapy, Cancer, Tumor growth modeling, Oxygen, Animal model studies, Picosecond phenomena, Tissues, In vitro testing, Molecules

Read Abstract +

SPIE Journal Paper | 1 March 2010 Open Access

Dye-enhanced multimodal confocal microscopy for noninvasive detection of skin cancers in mouse models

Jesung Park, Pawel Mroz, Michael Hamblin, Anna Yaroslavsky

JBO, Vol. 15, Issue 02, 026023, (March 2010) https://doi.org/10.1117/12.10.1117/1.3394301

KEYWORDS: Luminescence, Reflectivity, Confocal microscopy, Melanoma, In vivo imaging, Skin cancer, Tumors, Cancer, Tissues, Confocal fluorescent microscopy

Read Abstract +

DOWNLOAD PAPER

Proceedings Article | 11 February 2010 Paper

Photodynamic therapy for cancer and activation of immune response

Pawel Mroz, Ying-Ying Huang, Michael Hamblin

Proceedings Volume 7565, 756503 (2010) https://doi.org/10.1117/12.841031

KEYWORDS: Tumors, Photodynamic therapy, Cancer, Proteins, Molecules, Receptors, Oxygen, Picosecond phenomena, Signal processing, Animal model studies

Read Abstract +

Proceedings Article | 13 July 2009 Paper

New stable synthetic bacteriochlorins for photodynamic therapy of melanoma

Pawel Mroz, Ying-Ying Huang, Sahar Janjua, Timur Zhiyentayev, Christian Ruzié, K. Eszter Borbas, Dazhong Fan, Michael Krayer, Thiagarajan Balasubramanian, Eun Kyung Yang, Hooi Ling Kee, Dewey Holten, Jonathan Lindsey, Michael Hamblin

Proceedings Volume 7380, 73802S (2009) https://doi.org/10.1117/12.823060

KEYWORDS: Melanoma, Photodynamic therapy, Picosecond phenomena, Tumors, Luminescence, Absorption, In vitro testing, Control systems, Near infrared, Skin cancer

Read Abstract +

Proceedings Article | 13 July 2009 Paper

Anti-tumor immune response after photodynamic therapy

Pawel Mroz, Ana Castano, Mei Wu, Andrew Kung, Michael Hamblin

Proceedings Volume 7380, 73800F (2009) https://doi.org/10.1117/12.822994

KEYWORDS: Tumors, Photodynamic therapy, Lymphatic system, Proteins, Cancer, Colon, Tumor growth modeling, Molecules, Oncology, In vitro testing

Read Abstract +

Anti-tumor immunity is stimulated after PDT due a number of factors including: the acute inflammatory response caused by PDT, release of antigens from PDT-damaged tumor cells, priming of the adaptive immune system to recognize tumor-associated antigens (TAA), and induction of heat-shock proteins. The induction of specific CD8+ T-lymphocyte cells that recognize major histocompatibility complex class I (MHC-I) restricted epitopes of TAAs is a highly desirable goal in cancer therapy as it would allow the treatment of tumors that may have already metastasized. The PDT killed tumor cells may be phagocytosed by dendritic cells (DC) that then migrate to draining lymph nodes and prime naïve T-cells that recognize TAA epitopes. We have carried out in vivo PDT with a BPD-mediated vascular regimen using a pair of BALB/c mouse colon carcinomas: CT26 wild type expressing the naturally occurring retroviral antigen gp70 and CT26.CL25 additionally expressing beta-galactosidase (b-gal) as a model tumor rejection antigen. PDT of CT26.CL25 cured 100% of tumors but none of the CT26WT tumors (all recurred). Cured CT26.CL25 mice were resistant to rechallenge. Moreover mice with two bilateral CT26.CL25 tumors that had only one treated with PDT demonstrated spontaneous regression of 70% of untreated contralateral tumors. T-lymphocytes were isolated from lymph nodes of PDT cured mice that recognized a particular peptide specific to b-gal antigen. T-lymphocytes from LN were able to kill CT26.CL25 target cells in vitro but not CT26WT cells as shown by a chromium release assay. CT26.CL25 tumors treated with PDT and removed five days later had higher levels of Th1 cytokines than CT26 WT tumors showing a higher level of immune response. When mice bearing CT26WT tumors were treated with a regimen of low dose cyclophosphamide (CY) 2 days before, PDT led to 100% of cures (versus 0% without CY) and resistance to rechallenge. Low dose CY is thought to deplete regulatory T-cells (Treg, CD4+CD25+foxp3+) and potentiate immune response after PDT in the case of tumors that express self-antigens. These data suggest that PDT alone will stimulate a strong immune response when tumors express a robust antigen, and in cases where tumors express a self-antigen, T-reg depletion can unmask the immune response after PDT.

Proceedings Article | 13 July 2009 Paper

Combination of PDT and a DNA demethylating agent produces anti-tumor immune response in a mouse tumor model

Pawel Mroz, Michael Hamblin

Proceedings Volume 7380, 73800H (2009) https://doi.org/10.1117/12.823005

KEYWORDS: Tumors, Photodynamic therapy, Cancer, Proteins, Cell death, Tumor growth modeling, Molecules, Picosecond phenomena, Oxygen, In vivo imaging

Read Abstract +

Proceedings Article | 25 February 2009 Paper

Stimulation of dendritic cells enhances immune response after photodynamic therapy

Pawel Mroz, Ana Castano, Michael Hamblin

Proceedings Volume 7178, 717803 (2009) https://doi.org/10.1117/12.809630

KEYWORDS: Tumors, Photodynamic therapy, Cancer, Receptors, Bone, Lymphatic system, Tumor growth modeling, Molecules, Breast cancer, In vitro testing

Read Abstract +

Proceedings Article | 18 February 2008 Paper

Photodynamic therapy stimulates anti-tumor immunity in a murine mastocytoma model

Pawel Mroz, Michael Hamblin

Proceedings Volume 6857, 685706 (2008) https://doi.org/10.1117/12.764922

KEYWORDS: Tumors, Photodynamic therapy, In vitro testing, Molecules, Proteins, Oxygen, Cancer, Tissues, Cell death, Therapeutics

Read Abstract +

Proceedings Article | 13 February 2007 Paper

Photodynamic therapy stimulates anti-tumor immunity in a murine model

Pawel Mroz, Ana Castano, Mei Wu, Andrew Kung, Michael Hamblin

Proceedings Volume 6438, 643803 (2007) https://doi.org/10.1117/12.697630

KEYWORDS: Tumors, Photodynamic therapy, Cancer, Tumor growth modeling, Proteins, Oxygen, Colon, Computer programming, In vivo imaging, Potassium

Read Abstract +

Cancer is a leading cause of death among modern peoples largely due to metastatic disease. The ideal cancer treatment should target both the primary tumor and the metastases with the minimal toxicity. This is best accomplished by educating the body's immune system to recognize the tumor as foreign so that after the primary tumor is destroyed, distant metastases will also be eradicated. Photodynamic therapy (PDT) involves the IV administration of photosensitizers followed by illumination of the primary tumor with red light producing reactive oxygen species that cause vascular shutdown and tumor cell apoptosis. Anti-tumor immunity is stimulated after PDT due to the acute inflammatory response, priming of the immune system to recognize tumor-associated antigens (TAA), and induction of heat-shock proteins. The induction of specific CD8+ T lymphocyte cells that recognize major histocompatibility complex class I (MHC-I) restricted epitopes of TAAs is a highly desirable goal in cancer therapy. We here report on PDT of mice bearing tumors that either do or do not express an established TAA. We utilized a BALB/c colon adenocarcinoma cell line termed CT26.CL25 retrovirally transduced to stably express &bgr;-galactosidase ( &bgr;-gal, a bacterial protein), and its non-&bgr;-gal expressing wild-type counterpart termed CT26 WT, as well as the control cell line consisting of CT26 transduced with the empty retroviral vector termed CT26-neo. All cells expressed class I MHC restriction element H-2Ld syngenic to BALB/c mice. Vascular PDT with a regimen of 1mg/kg BPD injected IV, and 120 J/cm² of 690-nm laser light after 15 minutes successfully cured 100% of CT26.CL25 tumors but 0% of CT26-neo tumors and 0% of CT26 WT tumors. After 90 days tumor free interval the CT26.CL25 cured mice were rechallenged with CT26.CL25 tumor cells and 96% rejected the rechallenge while the CT26.CL25 cured mice did not reject a CT26 WT tumor cell challenge. Experiments with mice bearing two CT26.CL25 tumors (one in each leg) and only one tumor treated with PDT, showed that the immune response was strong enough to destroy an already established tumor in 70 of the mice and this effect was not seen with mice bearing two CT26 WT tumors. We expect these studies will lead to an understanding of the relevant determinants of immune response after PDT that could be rapidly applied to patient-selection and improvement in outcome for PDT for cancer.

Proceedings Article | 24 February 2006 Paper

Combination immunotherapy and photodynamic therapy for cancer

Michael Hamblin, Ana Castano, Pawel Mroz

Proceedings Volume 6087, 608702 (2006) https://doi.org/10.1117/12.646275

KEYWORDS: Tumors, Photodynamic therapy, Cancer, Receptors, Therapeutics, Lymphatic system, Cell death, Oxygen, Proteins, Resistance

Read Abstract +

Showing 5 of 11 publications

View contact details

UPDATE YOUR PROFILE

Is this your profile? Update it now.

Sign into your SPIE.org account

Don’t have a profile and want one?

Create an account on SPIE.org

Keywords/Phrases

Search In:

Publication Years